Compare Alcon AG (ALC) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Equinor ASA — how do they compare? Alcon AG trades at $73.19 (market cap $36.44B), while Equinor ASA trades at $40.79 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 2.7× Alcon AG's market cap, and Equinor ASA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ALC | EQNR | |
|---|---|---|
Market Cap | $36.44B | $97.58B |
Sector | Health | Energy |
52-Week High | $90.12 | $42.40 |
52-Week Low | $62.02 | $22.41 |
Enterprise Value | $40.28B | $106.28B |
Dividend Yield | 0.48% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
EQNR trades at $40.99, up 5.32% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 40% year-over-year despite an earnings miss, driven by higher energy prices and production. Recent news highlights a 22.2% monthly rally and ongoing share buybacks. Valuation ratios appear attractive with a P/E of 11.09 and EV/EBITDA of 2.3, while profitability metrics like a 21.32% ROE indicate efficient capital use.
The outlook for EQNR is positive, with opportunities from strategic investments in subsea projects and sustained cash flow generation supporting dividends and buybacks. Risks include volatility in oil and gas prices, execution challenges in growth projects, and potential regulatory shifts impacting energy markets. Analyst sentiment is mixed but leans cautious, with 56.53% holding a neutral stance amid valuation concerns after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
